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Controllable Immunosuppression 
in Pigs as a Basis for Preclinical 
Studies on Human Cell Therapy
Shin Enosawa and Eiji Kobayashi
Abstract
Along with a growing interest in regenerative medicine, pigs are becoming a 
popular model for preclinical studies on human cell therapy. Due to pharmaceuti-
cal species difference and inability to self-medicate, specific modification and care 
are necessary in immunosuppressive regimen for pigs. Here, we summarize recent 
literature on immunosuppression in pigs for experimental transplantation. Based 
on literature and our own experiences, a practical protocol has been proposed in 
this report. In early studies of allogeneic organ transplantation, recipient pigs were 
administered cyclosporine or tacrolimus, and mycophenolate mofetil at slightly 
higher dose than that in human cases, because of relatively poor effectiveness of the 
drugs in pigs. Steroids may be effective but sometimes can cause debilitating side 
effects. Cell transplantation studies follow the basic protocol, but it remains to be 
clarified whether the smaller graft mass, even if it is xenogeneic, requires the same 
scale of immunosuppression as organ transplantation. To obtain reliable results, 
the use of gastrostomy tube and blood trough level monitoring are highly recom-
mended. Nonpharmaceutical immunosuppression such as thymic intervention and 
the use of severe combined immunodeficient pigs have also been discussed.
Keywords: pig, experimental transplantation, immunosuppression, human cell 
therapy, regenerative medicine
1. Introduction
The number of preclinical studies conducted using pigs has been increasing, 
especially in the field of cell therapy [1]. The merits of using pigs include (1) size 
advantages that enable to mimic clinical procedures; (2) availability of various 
experimental pigs such as miniature, microminiature, and gene-engineered strains; 
and (3) worldwide trend of discouragement of using dogs as research models.
However, immunosuppressive treatment has not been established well in pigs. 
Initially, pigs were used as models for performing allogeneic organ transplanta-
tion; now, the hope is to use them as xenogeneic organ donors. In the latter case, 
immunosuppressive protocols have been designed for primate recipients, while 
the number of reports mentioning immunosuppressive protocols for xenogeneic 
transplantation in pigs is unexpectedly few. In addition, insufficient medications 
are occasionally found in studies conducted by researchers who are not accustomed 
to organ transplantation.
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We summarize here the pharmaceutical immunosuppressive regimens in 
experimental transplantation of organs, tissues, and cells in pigs (Table 1), as well 
as highlight the usefulness of thymic intervention and severe combined immunode-
ficient (SCID) pigs. Finally, we propose an appropriate introductory protocol that 
will fit human cell and tissue transplantation.
Study design Pigs Immunosuppression
In vitro culture, IC50 
estimation [2]
Unknown Cys, Tac, Aza, Rap, MMF, MP
Orthotopic allogeneic small 
bowel transplantation [3, 4]
Large White × 
Landrace, 26.4 ± 4.7 kg
Tac 0.43 ± 0.14 mg/kg/day, po (keep trough 
5–15 ng/ml), MMF 10 mg/kg × 2/day, po
Trough level determination 
[5]
Yorkshire × Landrace, 
22–30 kg
Tac 0.25 mg/kg × 2/day, po, MMF 20 mg/
kg × 2/day, po
Orthotopic allogeneic 
forelimb transplantation 
[6, 7]
Outbred farm 
pig, 13–24 kg 
(6–8-week-old)
Cys 40 mg/kg/day, po (keep trough 
100–300 ng/ml) or Tac 1.5 mg/kg/day, po (keep 
trough 4–8 ng/ml), MMF 500 mg/day, MP and 
P (tapered)
Orthotopic allogeneic 
(Class I disparate) kidney 
transplantation [8–10]
MHC-defined 
miniature swine, 
5–7-month-old
Cys 10–13 mg/kg/day, iv (keep trough 
400–800 ng/ml) [8, 9] or Tac 0.15 or 0.30 mg/
kg/day, iv (keep trough 20–40 or 45–80 ng/
ml) [10]
Heterotopic allogeneic 
(Class I disparate) heart 
transplantation [11]
MHC-defined 
miniature swine, 
3–6-month-old
MMF 1.5 g × 2 /day, iv or Cys 10–13 mg/kg/day, 
iv (keep trough 400–800 ng/ml)
Immortalized human 
hepatocytes transplantation 
to liver [13]
Landrace, 6 kg Tac 0.5 mg/kg/day, im
Human bone marrow 
mesenchymal stem 
cell transplantation to 
myocardium [14]
Domestic pig, 
35–40 kg
Cys 5 mg/kg/day, route unknown
Human umbilical 
mesenchymal stem cell 
transplantation to cardiac 
muscle [15, 16]
Yorkshire, size and age 
unknown
Cys 4–10 mg/kg/day, po, 1–2/day, some cases 
treated with steroids
Human iPS cell-derived 
cardiomyocyte sheet to 
endocardium [18]
Minipig, 20–25 kg Tac 0.75 mg/kg/day, MMF 500 mg/day, Pl 
20 mg/day
Human ES cell-derived 
retinal sheet to retina [19]
Yucatan minipig Cys, po, details unknown
Orthotopic allogeneic 
(Class I disparate) kidney 
transplantation [20]
MHC-defined 
miniature swine, 
3–6-month-old
Thymectomy and donor thymus 
transplantation
Human hepatocyte 
transplantation to spleen 
[21]
Microminiature pig, 
13–16-month-old
Neonatal thymectomy
Human artificial 
vascular tubes for neck 
arteriovenous shunt [22]
Göttingen minipigs, 
6–7-month-old, 
≥15 kg
Thymectomy and splenectomy, and Tac 0.5 mg/
kg/day, MMF 60 mg/kg/day, prednisolone 
20 mg/day, po
Abbreviations: half maximal inhibitory concentration (IC50); major histocompatibility complex (MHC); cyclosporine 
(Cys); tacrolimus (Tac); azathioprine (Aza); rapamycin (rap); mycophenolate mofetil (MMF); methylprednisolone 
(MP); prednisone (P); prednisolone (Pl); per os (po); intravenous injection (iv); intramuscular injection (im).
Table 1. 
Summary of immunosuppressive protocols.
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2.  Role of species differences in the effectiveness of 
immunosuppressants in vitro
The half maximal inhibitory concentration (IC50) of major immunosuppres-
sants was reported to be higher in mitogen response of pig lymphocytes than that in 
human lymphocytes [2]. The IC50 of cyclosporine, tacrolimus, and azathioprine was 
19.1 times [1.72 μg/ml (pig) vs. 0.09 μg/ml (human)], 13.0 times [2.99 ng/ml (pig) 
vs. 0.23 ng/ml (human)], and 11.0 times [1.43 μg/ml [pig] vs. 0.13 μg/ml (human)] 
higher in pigs than in human lymphocytes, respectively. The species differences 
decreased in case of rapamycin and mycophenolate mofetil (MMF); IC50 values of 
rapamycin and MMF were 2.28 times [2.05 ng/ml (pig) vs. 0.90 ng/ml (human)] 
and 1.45 times [10.75 ng/ml (pig) vs. 7.42 ng/ml (human)] higher in pigs than in 
humans, respectively. In contrast, the IC50 value of methylprednisolone in pigs was 
only 0.41 times [0.11 μg/ml (pig) vs. 0.27 μg/ml (human)] the value in humans. 
These results suggest that the blood concentration of calcineurin inhibitors should 
be kept higher in pigs than in humans to suppress blast formation of lymphocytes in 
transplantation studies.
3. Immunosuppressive medications in allogeneic transplantation
In allogeneic orthotopic small bowel transplantation, high-dose tacrolimus 
monotherapy and low-dose tacrolimus-MMF combination therapy were compared 
using Large White-Landrace pig strain as donors and recipients (both weigh-
ing approximately 26 kg) [3, 4]. Tacrolimus dose was controlled to keep trough 
at 15–25 ng/ml (high-dose group) or 5–15 ng/ml (low-dose group). The average 
dosage amount of tacrolimus in the high single dose group was 0.3 mg/kg/day 
intramuscularly from the day of operation to day 6 and 0.61 ± 0.26 mg/kg/day 
via gastrostomy after day 7. In the low-dose combination group, recipients were 
administered 0.1 mg/kg of tacrolimus intramuscularly on the day of operation and 
0.43 ± 0.14 mg/kg/day (average) of tacrolimus and 10 mg/kg twice a day of MMF 
via gastrostomy. All recipients in the high single dose group died within 46 days, 
while 7 out of the 10 recipients in the low-dose combination group survived for 
more than 60 days; the nontreated controls died within 15 days [3]. The subgroup 
study of tacrolimus-MMF combined group revealed that the recipients with low 
trough level of tacrolimus showed better survival, suggesting that higher trough 
level increases side effects of infection [4]. In general, the protocol consisting of cal-
cineurin inhibitors (cyclosporine or tacrolimus) and MMF suppresses the immune 
responses of T and B cells, respectively, and the combination treatment leads to 
effective immunosuppression with low side effects.
A pharmacokinetic study recommended the oral administration of 0.25 mg/kg of 
tacrolimus and 500 mg of MMF at 12 h intervals to pigs weighing 22–30 kg [5]. MMF 
dose was calculated to be around 20 mg/kg at each administration. The trough level 
of tacrolimus was kept at 5–15 ng/ml.
When orthotopic forelimb transplantation was performed between outbred 
pigs weighing 13–24 kg, recipients were administered cyclosporine or tacrolimus 
and MMF orally once a day [6, 7]. The desired trough levels were 100–300 ng/ml in 
case of cyclosporine and 3–8 ng/ml for tacrolimus. A total of 500 mg of MMF was 
administered, i.e., 21–38 mg/kg. They also used steroids; 500 mg of methylpred-
nisolone was injected intravenously during the operation, and 2.0 mg/kg/day of 
prednisone was given on the first postoperative day and then tapered by 0.5 mg/kg/
day every 3 days to a maintenance dose of 0.1 mg/kg/day until the end of observa-
tion period (90 days) [6] or for the first 30 days [7].
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The Massachusetts General Hospital group uses genetically defined mini pigs, 
swine leukocyte antigen (SLA)gg (class Ic/class IId) donors, and SLAdd (class Id/class 
IId) recipients [8–11]. In orthotopic kidney transplantation, 10–13 mg/kg of cyclo-
sporine once a day, administered with a catheter to the external jugular vein, kept 
the trough level at 400–800 ng/ml [8, 9]. The first 12-day administration resulted 
in the survival of well-functioning major histocompatibility complex (MHC) class 
I-disparate kidney grafts for over 90 days regardless of use of steroids. In another 
study [10], continuous intravenous injection of 0.15 or 0.30 mg/kg/day of tacrolimus 
treatment kept the drug level at 20–40 or 45–80 ng/ml, respectively, and the first 
12-day administration resulted in well-functioning kidney grafts that survived for 
over 5 months. In addition, the high-dose regimen achieved successful engraftment of 
MHC class Ic/class IIc-mismatched kidney. The same group also compared the sepa-
rate effect of cyclosporine and MMF on the survival of class I-disparate heterotopic 
heart graft [11]. The treatment protocol of cyclosporine was the same as above [8] 
and MMF was administered at 1.5 g twice a day through a catheter into the external 
jugular vein to keep the trough level at 3–5 μg/ml. The survival days of the test heart 
grafts were 53 ± 7.5 days (mean ± SD) and over 124 days in cyclosporine and MMF 
groups, respectively. The graft vascular changes were also mild in the MMF group.
4. Immunosuppressive medications in xenogeneic transplantation
Because pigs are hoped to be a xenogeneic donor, the major objectives in pig 
experiments include establishing xenogeneic antigen-free pigs and developing 
strategies for long-term survival in nonhuman primates [12]. In such studies, 
immunosuppression is almost equivalent to human clinics using tacrolimus, MMF, 
and antibody remedies. Pig recipients in xenotransplantation appear in the preclini-
cal studies of human cell and tissue therapy.
In a short-term experiment of intrahepatic transplantation of human hepatocyte 
cell line, 0.5 mg/kg of tacrolimus was injected intramuscularly for 7 days [13]. 
When pigs received xenogeneic human-lined hepatocytes, the recipients survived 
D-galactosamine-induced hepatic injury. Human albumin appeared in the recipient 
serum 2 days after transplantation but disappeared at day 7, suggesting that the cells 
survived only for a few days.
Intramyocardial transplantation of mesenchymal stem cells had been actively 
investigated in not only basic research but also clinical practice. Because of the 
size advantage, pigs were used for preclinical studies to explore proof of concept 
by mimicking clinical procedure. Human bone marrow-derived mesenchymal 
stem cells labeled with radioactive indium (111In) were transplanted in porcine 
myocardium via catheter inserted from a femoral artery and traced by whole body 
scanning for 6 days [14]. Recipient pigs were orally treated with 5 mg/kg of cyclo-
sporine from 3 days before to 6 days after cell transplantation. Immunosuppressed 
pigs retained the radioactivity far longer than nontreated controls. In another study, 
pigs received human umbilical mesenchymal stem cells in artificial cardiac infarct 
area and were administered 5 mg/kg of cyclosporine orally twice a day, from the 
day before to 8 weeks after cell transplantation [15]. In a similar study, 10 mg/kg 
of cyclosporine was administered orally, twice a day from 3 days before to 8 weeks 
after the cell transplantation [16]. As a more sophisticated approach, cardiomyocyte 
sheet transplantation is being undertaken [17, 18]. When cell sheets consisting of 
human induced pluripotent stem (iPS) cell-derived myocytes were transplanted 
onto the epicardium of minipigs (weighing 20–25 kg) mimicking clinical trial, 
0.75 mg/kg/day of tacrolimus, 500 mg/day of MMF, and 20 mg/day of prednisolone 
were administered from 5 days before to 8 weeks after the transplantation [18].
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Transplantation of human embryonic stem cell-derived retinal pigmented 
epithelium was also performed in pigs [19]. Although immunosuppression was 
precarious, cyclosporine was added in the feed and their blood level 2 h after 
administration was only 1 pg/ml, and the graft tissue was detectable after 3 months. 
Because retina is known as an immune-privileged site, additional immunosuppres-
sion may not be necessary.
5.  Nonpharmaceutical immunosuppression: thymic intervention and 
SCID pigs
Studies on genetically defined minipigs by Massachusetts General Hospital 
group emphasize the role of thymus in the establishment and maintenance of 
immunological tolerance. As quoted above [8], the 12-day administration of 
cyclosporine induced the long-term engraftment of MHC class I-disparate kid-
neys, but not if the thymus was removed. They also stated that old recipients tend 
to be difficult to establish tolerance [9]. These observations lead to the concept 
of tolerance induction by thymic transplantation. In this, unlike conventional 
thymic tissue transplantation, the donor thymus is transplanted by vascular 
anastomosis that assures immediate and perfect function of the thymus. Three 
weeks after the complete removal of thymus, the recipient was transplanted with 
MHC fully-disparate donor thymus in the neck region and infused continuously 
with 0.15 mg/kg/day of tacrolimus (trough level, 30–40 ng/ml) for 12 days. After 
3–4 months, the recipient accepted a kidney from the thymus donor without 
immunosuppression [20].
Previously, we reported the effectiveness of thymectomy on the acceptance of 
xenogeneic human hepatocytes and artificial vascular tubes [21, 22]. Upon hepa-
tocyte transplantation, the blood human albumin levels were higher in neonatally-
thymectomized microminiature pigs than in nonthymectomized controls [21]. In 
another study, thymus and spleen were removed from Göttingen minipigs aged 
6–7 months (≥ 15 kg), followed by the administration of 0.5 mg/kg/day of tacro-
limus, 60 mg/kg/day of MMF, and 20 mg/day of prednisolone [22]. Seven days 
after the removal, an artificial vascular tube made from human fibroblasts was 
transplanted in between a carotid artery and a jugular vein to form an arteriovenous 
shunt. While the shunt was obstructed completely by thrombus 2 weeks after the 
operation in pigs without the removal of thymus and spleen, the shunt was func-
tional in pigs with thymectomy and splenectomy, even though the immunosuppres-
sive treatment administered was equal.
Finally, we would like to refer briefly to the availability of SCID pigs in preclini-
cal study on human cell therapy. According to a well-constructed review [23], there 
are 11 SCID pig strains so far; one was naturally found and others were genetically 
modified. The mutated genes in these strains are ARTEMIS (a gene encoding a 
nuclear protein that is involved in V(D)J recombination and DNA repair), inter-
leukin 2 receptor gamma chain (IL2RG), recombination-activating genes (RAG)1, 
and RAG2. Three strains have double mutations, namely RAG1 and 2, RAG2 and 
IL2RG, and ARTEMIS and IL2RG. In accordance with gene function, each strain 
lacks specific immune-competent cell lineages such as T, B, and natural killer (NK) 
cells. Human cell transplant experiments were reported as iPS cell teratoma forma-
tion [24] and ovarian cancer engraftment [25], both of which did not focus on 
preclinical study on human cell therapy. SCID pigs need the highest antibacterial 
care because of their vulnerability to infection. Indeed, they have been reported 
to survive for only 6 months at the longest [23]. In addition, as general features 
of mutant pigs, there are diversities in phenotypic severity and small litter size. If 
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these difficulties can be overcome, SCID pigs will be useful experimental animals 
for preclinical study on human cell therapy.
6. Conclusion
Due to the lack of identifiable sign of rejection, immunosuppression in cell 
transplant experiment is hard to control. Successful protocol is established only 
based on case-by-case experiences. Here, we suggest an introductory regimen 
of immunosuppression in human cell and tissue transplantation into pigs using 
tacrolimus and MMF. Preliminary doses are 0.5 mg/kg of tacrolimus orally and 
40 mg/kg of MMF orally, and the administration should start 3 and 5 days before 
transplantation, respectively. Drugs can be administered by mixing in the powdered 
feed before transplantation; however, after transplantation, it should be given 
through a gastrostomy tube to assure the dosage in order to not be affected by 
appetite. Periodical examination of drug trough levels is indispensable and should 
be reflected in subsequent dose. Steroids should be carefully tested because their 
immunosuppressive dose has a risk of side effects such as gastrointestinal ulcer and 
systemic over immunosuppression. In addition, unavailability of exogenous steroid 
monitoring makes dosage control difficult. If surgical skill is available, the combi-
nation of thymectomy and splenectomy is recommended. Since the graft mass of 
cell and tissue transplantation is far smaller and not fully vascularized than organs, 
the recipients may need less immunosuppression. Data accumulation and optimiza-
tion are desired in this field.
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